Stereoselective hexobarbital 3′-hydroxylation by CYP2C19 expressed in yeast cells and the roles of amino acid residues at positions 300 and 476

Chirality

Volumn 19, Issue 7, 2007, Pages 550-558

  Saito, Keita ^a   Dan, Hikari ^a   Masuda, Kazufumi ^a   Katsu, Takashi ^a   Hanioka, Nobumitsu ^a   Yamamoto, Shigeo ^b   Miyano, Kazuko ^c   Yamano, Shigeru ^c   Narimatsu, Shizuo ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b MATSUYAMA UNIVERSITY   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

CYP2C19; Enantiomer; Glutamic acid 300; Hexobarbital; Phenylalanine 476; Site directed mutagenesis; Substrate enantioselectivity

Indexed keywords

CYTOCHROME P450 2C19; HEXOBARBITAL;

AMINO ACID COMPOSITION; AMINO ACID SUBSTITUTION; ARTICLE; ENANTIOMER; ENANTIOSELECTIVITY; ENZYME ANALYSIS; ENZYME SUBSTRATE; HYDROXYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; SITE DIRECTED MUTAGENESIS; STEREOCHEMISTRY; WILD TYPE; YEAST CELL;

AMINO ACID SUBSTITUTION; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; CATALYTIC DOMAIN; DNA PRIMERS; HEXOBARBITAL; HUMANS; HYDROXYLATION; MIXED FUNCTION OXYGENASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; PLASMIDS; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 34250831484     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20412     Document Type: Article

References (27)

1. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997;29:413-580.
2. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll M. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004;199:193-209.
3. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-491.
4. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004;25:193-200.
5. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-1752.
6. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996;60:661-666.
7. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-355.
8. Desta Z, Zhao X, Shin J-G, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-958.
9. Adedoyin A, Prakash C, O'Shea D, Blair IA, Wilkinson GR. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 1994;4:27-38.
10. Yausmori T, Murayama N, Yamazoe Y, Kato R. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereosomers in relation to hepatic P450 huamn-2. Clin Pharmacol Ther 1990;47:313-322.
11. Yasumori T, Yamazoe Y, Kato R. Cytochrome P-450 human-2 (P-450IIC9) in mephenytoin hydroxylation polymorphism in human livers: differences in substrate and stereoselectivities among microheterogeneous P-450IIC species expressed in yeasts. J Biochem 1991;109:711-717.
12. Narimatsu S, Takemi C, Tsuzuki D, Kataoka H, Yamamoto S, Shimada N, Suzuki S, Satoh T, Meyer UA, Gonzalez FJ. Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes. J Pharmacol Exp Ther 2002;303:172-178.
13. Masuda K, Tamagake K, Katsu T, Torigoe F, Saito K, Hanioka N, Yamano S, Yamamoto S, Narimatsu S. The roles of phenylalanine at position 120 and glutamic acid at position 222 in the oxidation of chiral substrates by cytochrome P450 2D6. Chirality 2006;18:167-176.
14. Masuda K, Tamagake K, Okuda Y, Torigoe F, Tsuzuki D, Isobe T, Hichiya H, Hanioka N, Yamamoto S, Narimatsu S. Change in enantioselectivity in bufuralol 1″-hydroxylation by the substitution of phenylalanine-120 by alanine in cytochrome P450 2D6. Chirality 2005;17:37-43.
15. Williams PA, Cosme J, Ward A, Angove HC, Vinkovic DM, Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003;424:464-468.
16. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, Chenery RJ, Bridges AM. Crystal structure of human cytochrome P450 2D6. J Biol Chem 2006;281:7614-7622.
17. Ellis SW, Hayhurst GP, Smith G, Iightfoot T, Wong MMS, Simula AP, Ackland MJ, Sternberg MJE, Lennard MS, Tucker GT, Wolf CR. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem 1995;270: 29055-29058.
18. Hanna IH, Kim MS, Guengerich FP. Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: The role of aspartate 301 in structure integrity. Arch Biochem Biophys 2001;393:255-261.
19. Melet A, Assrir N, Jean P, Lopez-Garcia MP, Marques-Soares C, Jaouen M, Dansette PN, Sari M-A, Mansuy D. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch Biochem Biophys 2003;409:80-91.
20. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiederberg's Arch Pharmacol 2004;369:23-37.
21. Romanos MA, Scorer CA, Clare JJ. Foreign gene expression in yeast: a review. Yeast 1992;8:423-488.
22. Wan J, Imaoka S, Chow T, Hiroi T, Yabusaki Y, Funae Y. Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity. Arch Biochem Biophys 1997;348:383-390.
23. Hichiya H, Takemi C, Tsuzuki D, Yamamoto S, Asaoka K, Suzuki S, Satoh T, Shinoda S, Kataoka H, Narimatsu S. Complementary DNA cloning and characterization of cytochrome P450 2D29 from Japanese monkey liver. Biochem Pharmacol 2002;64:1101-1110.
24. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964;239:2370-2378.
25. Tsuzuki D, Takemi C, Yamamoto S, Tamagake K, Imaoka S, Funae Y, Kataoka H, Shinoda S, Narimatsu S. Functional evaluation of cytochrome P450 2D6 with Gly42Arg substitution expressed in Saccharomyces cerevisiae. Pharmacogenetics 2001;11:709-718.
26. Takenoshita R, Toki S. New aspects of hexobarbital metabolism: Stereoselective metabolism, new metabolic pathway via GSH conjugation, and 3-hydroxyhexobarbital dehydrogenases. Yakugaku Zasshi (J Pharm Soc Jpn) 2004;124:858-871. (in Japanese).
27. Miyano K, Fuji Y, Toki S. Stereoselective hydroxylation of hexobarbital enntiomers by rat liver microsomes. Drug Metab Dispos 1984;8: 104-109.